COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.85 | 7.60 | 7.95 | -1.42 |
| FCF Yield | -0.12% | -0.17% | -0.12% | 1.61% |
| EV / EBITDA | 10.68 | 9.02 | 9.91 | 9.44 |
| Quality | ||||
| ROIC | 9.47% | 8.47% | 9.37% | 10.23% |
| Gross Margin | 21.09% | 19.51% | 20.38% | 20.05% |
| Cash Conversion Ratio | 1.69 | 1.69 | 2.26 | 2.29 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.91% | 8.50% | 4.45% | 3.35% |
| Free Cash Flow Growth | 0.00% | -35.28% | -108.14% | 168.99% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | -0.34 | -0.55 | -0.58 |
| Interest Coverage | 159.07 | 318.19 | 590.75 | 573.00 |
| Efficiency | ||||
| Inventory Turnover | 8.64 | 9.01 | 8.51 | 9.10 |
| Cash Conversion Cycle | -34.37 | -39.27 | -42.23 | -39.89 |